Microemulsion-based antifungal gel delivery to nail for the treatment of onychomycosis: formulation, optimization, and efficacy studies

Drug Delivery and Translational Research
Bhavesh S BarotPragna K Shelat

Abstract

Onychomycosis is the most common nail disease affecting nail plate and nail bed. Onychomycosis causes onycholysis which creates cavity between the nail plate and nail bed, where drug formulations could be applied, providing a direct contact of drug with the nail bed facilitating drug delivery on the infected area. The purpose of the present study was to design and evaluate the potential of microemulsion-based gel as colloidal carrier for itraconazole for delivery into onycholytic nails for effective treatment of onychomycosis. Itraconazole-loaded microemulsions were prepared and optimized using D-optimal design. The microemulsion containing 6.24 % oil, 36 % Smix, and 57.76 % water was selected as the optimized batch (MEI). The globule size and drug loading of the optimized batch were 48.2 nm and 12.13 mg/ml, respectively. Diffused reflectance FTIR studies were performed to study drug-excipient incompatibility. Ex vivo permeation studies were carried out using bovine hoof and human cadaver skin as models for nail plate and nail bed, respectively. Microemulsion-based itraconazole gel (MBGI) showed better penetration and retention in human skin as well as bovine hoof as compared to commercial preparation (market formulation, MFI)....Continue Reading

References

May 20, 1998·International Journal of Dermatology·A K GuptaR Baran
May 27, 1999·The Journal of Pharmacy and Pharmacology·Y KobayashiY Morimoto
Jul 30, 1999·Journal of Controlled Release : Official Journal of the Controlled Release Society·M Trotta
Dec 6, 2000·Advanced Drug Delivery Reviews·M J Lawrence, G D Rees
Aug 28, 2001·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·E LarruceaP Ygartua
Mar 14, 2002·International Journal of Pharmaceutics·Sudaxshina Murdan
May 7, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kohsaku KawakamiKazuyoshi Masuda
Dec 4, 2002·Advanced Drug Delivery Reviews·Mads Kreilgaard
Mar 8, 2003·International Journal of Pharmaceutics·S PeltolaA Urtti
Oct 23, 2003·Dermatology : International Journal for Clinical and Investigative Dermatology·Jorge E Arrese, Gérald E Piérard
Aug 5, 2004·Contact Dermatitis·David A BasketterMichael K Robinson
Jan 15, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·R Baran, A Kaoukhov
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Robert BaranGerald E Piérard
Apr 8, 2006·International Journal of Pharmaceutics·Huabing ChenXiangliang Yang
Apr 14, 2006·Current Drug Delivery·P K Ghosh, R S R Murthy
Jun 16, 2007·International Journal of Pharmaceutics·Huabing ChenXiangliang Yang
Jul 12, 2007·AAPS PharmSciTech·Sheikh Shafiq-un-NabiMushir Ali
Aug 19, 2007·Journal of Pharmaceutical Sciences·Sandra HeuschkelReinhard H H Neubert
Sep 4, 2007·International Journal of Pharmaceutics·Yaw Bin HuangPao Chu Wu
Feb 5, 2008·International Journal of Pharmaceutics·Gamal M El Maghraby
Jun 11, 2008·International Journal of Pharmaceutics·Weiwei ZhuGuangxi Zhai
Sep 11, 2008·Journal of Pharmaceutical Sciences·Anroop B NairS Narasimha Murthy
Nov 4, 2008·Expert Opinion on Drug Delivery·Sudaxshina Murdan
Jan 1, 2009·Journal of Pharmaceutical Sciences·Jinsong HaoS Kevin Li
May 12, 2009·Expert Opinion on Investigational Drugs·Sandeep Kumar, Alexa B Kimball
May 26, 2009·International Journal of Pharmaceutics·Weiwei ZhuGuangXi Zhai
Jun 2, 2009·International Journal of Pharmaceutics·Anroop B NairS Narasimha Murthy
Sep 30, 2009·The British Journal of Dermatology·B AmichaiA Shemer
Jul 20, 2010·International Journal of Pharmaceutics·Pallavi V Pople, Kamalinder K Singh
Dec 1, 1996·Toxicology in Vitro : an International Journal Published in Association with BIBRA·E BoelsmaM Ponec
Apr 5, 2011·Drug Development and Industrial Pharmacy·Anroop B NairS Narasimha Murthy
Apr 27, 2012·Expert Opinion on Pharmacotherapy·Aditya K Gupta, Fiona C Simpson
May 9, 2012·Indian Journal of Dermatology, Venereology and Leprology·Chander Grover, Ananta Khurana
Oct 1, 2011·Drug Delivery and Translational Research·Sanyog JainNitin K Swarnakar

❮ Previous
Next ❯

Citations

Dec 23, 2016·The Journal of Physical Chemistry. B·Muhammad Faizan NazarMuhammad Zubair
Mar 12, 2019·Anti-inflammatory & Anti-allergy Agents in Medicinal Chemistry·Swati JagdaleAnuruddha Chabukswar
Aug 28, 2020·Nanomaterials·Giuseppe TartaroGerardo Palazzo
Aug 16, 2018·Langmuir : the ACS Journal of Surfaces and Colloids·Muhammad Faizan NazarAzwan Mat Lazim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.